AMGEN & AZ BRODALUMAB PHASE III RESULTS
AMGEN AND ASTRAZENECA ANNOUNCE POSITIVE RESULTS FROM PHASE III STUDY OF BRODALUMAB (AMG 827) IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints AstraZeneca and Amgen today announced that the Phase III AMAGINE-1TMstudy evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Brodalumab is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and